Immunotherapy with low dose interleukin-2 after cytoreductive chemotherapy for patients with hormone refractory metastatic prostate cancer: a phase I/II study.

Trial Profile

Immunotherapy with low dose interleukin-2 after cytoreductive chemotherapy for patients with hormone refractory metastatic prostate cancer: a phase I/II study.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2007

At a glance

  • Drugs Interleukin-2 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Nov 2007 Status changed from in progress to completed.
    • 25 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top